These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 23651481)
1. p38 Mitogen-activated protein kinase inhibitors: a review on pharmacophore mapping and QSAR studies. Gangwal RP; Bhadauriya A; Damre MV; Dhoke GV; Sangamwar AT Curr Top Med Chem; 2013; 13(9):1015-35. PubMed ID: 23651481 [TBL] [Abstract][Full Text] [Related]
2. Pharmacophore modeling of diverse classes of p38 MAP kinase inhibitors. Sarma R; Sinha S; Ravikumar M; Kishore Kumar M; Mahmood SK Eur J Med Chem; 2008 Dec; 43(12):2870-6. PubMed ID: 18406015 [TBL] [Abstract][Full Text] [Related]
3. Virtual screening based on pharmacophore model followed by docking simulation studies in search of potential inhibitors for p38 map kinase. Shahlaei M; Doosti E Biomed Pharmacother; 2016 May; 80():352-372. PubMed ID: 27133076 [TBL] [Abstract][Full Text] [Related]
4. Structure-based de novo design and synthesis of aminothiazole-based p38 MAP kinase inhibitors. Park H; Lee S; Hong S Bioorg Med Chem Lett; 2015 Sep; 25(18):3784-7. PubMed ID: 26259807 [TBL] [Abstract][Full Text] [Related]
5. Molecular modeling studies of phenoxypyrimidinyl imidazoles as p38 kinase inhibitors using QSAR and docking. Ravindra GK; Achaiah G; Sastry GN Eur J Med Chem; 2008 Apr; 43(4):830-8. PubMed ID: 17706839 [TBL] [Abstract][Full Text] [Related]
6. Identification of p38α MAP kinase inhibitors by pharmacophore based virtual screening. Gangwal RP; Das NR; Thanki K; Damre MV; Dhoke GV; Sharma SS; Jain S; Sangamwar AT J Mol Graph Model; 2014 Apr; 49():18-24. PubMed ID: 24473068 [TBL] [Abstract][Full Text] [Related]
7. Modeling of p38 mitogen-activated protein kinase inhibitors using the Catalyst HypoGen and k-nearest neighbor QSAR methods. Xiao Z; Varma S; Xiao YD; Tropsha A J Mol Graph Model; 2004 Oct; 23(2):129-38. PubMed ID: 15363455 [TBL] [Abstract][Full Text] [Related]
8. Free-energy force-field three-dimensional quantitative structure-activity relationship analysis of a set of p38-mitogen activated protein kinase inhibitors. Romeiro NC; Albuquerque MG; de Alencastro RB; Ravi M; Hopfinger AJ J Mol Model; 2006 Sep; 12(6):855-68. PubMed ID: 16541250 [TBL] [Abstract][Full Text] [Related]
9. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors. Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase. Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210 [TBL] [Abstract][Full Text] [Related]
12. Synthesis and biological evaluation of N-cyclopropylbenzamide-benzophenone hybrids as novel and selective p38 mitogen activated protein kinase (MAPK) inhibitors. Heo J; Shin H; Lee J; Kim T; Inn KS; Kim NJ Bioorg Med Chem Lett; 2015 Sep; 25(17):3694-8. PubMed ID: 26115577 [TBL] [Abstract][Full Text] [Related]
13. CoMFA and docking studies on triazolopyridine oxazole derivatives as p38 MAP kinase inhibitors. Shashi Nayana MR; Sekhar YN; Siva Kumari N; Mahmood SK; Ravikumar M Eur J Med Chem; 2008 Jun; 43(6):1261-9. PubMed ID: 17825954 [TBL] [Abstract][Full Text] [Related]
14. Insight into the structural determinants of imidazole scaffold-based derivatives as p38 MAP kinase inhibitors by computational explorations. Huang C; Li Y; Ren H; Wang J; Shao L; Zhang S; Li G; Yang L Curr Med Chem; 2012; 19(23):4024-37. PubMed ID: 22680637 [TBL] [Abstract][Full Text] [Related]
15. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors. Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937 [TBL] [Abstract][Full Text] [Related]
16. Novel lead structures for p38 MAP kinase via FieldScreen virtual screening. Cheeseright TJ; Holm M; Lehmann F; Luik S; Göttert M; Melville JL; Laufer S J Med Chem; 2009 Jul; 52(14):4200-9. PubMed ID: 19489590 [TBL] [Abstract][Full Text] [Related]
17. Structure-activity relationships of p38 mitogen-activated protein kinase inhibitors. Bolós J Mini Rev Med Chem; 2005 Sep; 5(9):857-68. PubMed ID: 16178727 [TBL] [Abstract][Full Text] [Related]
18. Discovery and characterization of non-ATP site inhibitors of the mitogen activated protein (MAP) kinases. Comess KM; Sun C; Abad-Zapatero C; Goedken ER; Gum RJ; Borhani DW; Argiriadi M; Groebe DR; Jia Y; Clampit JE; Haasch DL; Smith HT; Wang S; Song D; Coen ML; Cloutier TE; Tang H; Cheng X; Quinn C; Liu B; Xin Z; Liu G; Fry EH; Stoll V; Ng TI; Banach D; Marcotte D; Burns DJ; Calderwood DJ; Hajduk PJ ACS Chem Biol; 2011 Mar; 6(3):234-44. PubMed ID: 21090814 [TBL] [Abstract][Full Text] [Related]
19. Successful structure-based design of recent p38 MAP kinase inhibitors. Karcher SC; Laufer SA Curr Top Med Chem; 2009; 9(7):655-76. PubMed ID: 19689372 [TBL] [Abstract][Full Text] [Related]
20. Design, synthesis and characterization of N', N"-diaryl ureas as p38 kinase inhibitors. Kulkarni RG; Laufer S; Mangannavar C; Garlapati A Med Chem; 2013 Mar; 9(2):213-21. PubMed ID: 22946566 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]